3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
56
Carcinoma, Non-Small-Cell Lung
53
Carcinoma, Renal Cell
37
Lung Neoplasms
22
Neoplasm Metastasis
21
Carcinoma, Hepatocellular
21
Stomach Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
17
Neoplasms
17
Colorectal Neoplasms
17
Carcinoma, Transitional Cell
14
Adenocarcinoma Of Esophagus
13
Prostatic Neoplasms
11
Hodgkin Disease
11
Brain Neoplasms
10
Urinary Bladder Neoplasms
9
Ovarian Neoplasms
8
Multiple Myeloma
8
Triple Negative Breast Neoplasms
7
Skin Neoplasms
7
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Colonic Neoplasms
7
Clear-cell metastatic renal cell carcinoma
7
Breast Neoplasms
7
Sarcoma
6
Carcinoma, Merkel Cell
6
Carcinoma, Basal Cell
6
Uveal Melanoma
5
Interventions
belzutifan
3
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
Nivolumab
×
90 days
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled